Safe Accelerated Venetoclax Escalation in CLL

NCT04843904 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: Venetoclax
DRUG: Obinutuzumab
DRUG: Rituximab

Sponsor

Dana-Farber Cancer Institute